SV2A and Alzheimer disease: Recently, several studies have found that SV2A positron emission tomography (PET) imaging could be used as a biomarker of synaptic degeneration and AD pathology (Onwordi et al. 2024; Whiteside et al. 2023), which revealed the role of SV2A in AD progression.